{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abraxane+alone&page=2", "query": { "intervention": "Abraxane alone", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Abraxane+alone&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-28T01:27:18.125Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00492206", "title": "Study of Cetuximab With Radiation Followed by Consolidation Chemotherapy for NSCLC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer (NSCLC)" ], "interventions": [ { "name": "Cetuximab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 40, "start_date": "2006-06", "completion_date": "2012-02", "has_results": true, "last_update_posted_date": "2017-02-01", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 31, "location_summary": "Miami, Florida • Atlanta, Georgia • Baltimore, Maryland + 17 more", "locations": [ { "city": "Miami", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Steubenville", "state": "Ohio" }, { "city": "Beaver", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00492206" }, { "nct_id": "NCT05281471", "title": "Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Bevacizumab in Platinum-Resistant/Refractory Ovarian Cancer (PRROC) (OnPrime, GOG-3076)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Platinum-resistant Ovarian Cancer", "Platinum-refractory Ovarian Cancer", "Fallopian Tube Cancer", "Primary Peritoneal Cancer", "High-grade Serous Ovarian Cancer", "Endometrioid Ovarian Cancer", "Ovarian Clear Cell Carcinoma" ], "interventions": [ { "name": "olvimulogene nanivacirepvec", "type": "BIOLOGICAL" }, { "name": "Platinum chemotherapy: carboplatin (preferred) or cisplatin", "type": "DRUG" }, { "name": "Non-platinum chemotherapy: Physician's Choice of gemcitabine, taxane (paclitaxel, docetaxel or nab-paclitaxel) or pegylated liposomal doxorubicin", "type": "DRUG" }, { "name": "Bevacizumab (or biosimilar)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Genelux Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 186, "start_date": "2022-08-31", "completion_date": "2027-12", "has_results": false, "last_update_posted_date": "2026-08-26", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 33, "location_summary": "Mobile, Alabama • Tucson, Arizona • Duarte, California + 28 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Newport Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05281471" }, { "nct_id": "NCT03416153", "title": "Individualized Adaptive De-escalated Radiotherapy for HPV-related Oropharynx Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Oropharynx Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 91, "start_date": "2018-05-21", "completion_date": "2025-05-05", "has_results": true, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 2, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03416153" }, { "nct_id": "NCT05407675", "title": "A Study to Evaluate the Safety and Tolerability of BMS-986408 Alone and in Combination With Nivolumab or Nivolumab and Ipilimumab in Participants With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Solid Tumors" ], "interventions": [ { "name": "BMS-986408", "type": "DRUG" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Platinum-doublet chemotherapy", "type": "BIOLOGICAL" }, { "name": "Rabeprazole", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2022-08-02", "completion_date": "2025-07-24", "has_results": true, "last_update_posted_date": "2026-08-13", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 3, "location_summary": "Boston, Massachusetts • Hackensack, New Jersey • Houston, Texas", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Hackensack", "state": "New Jersey" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05407675" }, { "nct_id": "NCT07049055", "title": "A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Pancreatic Cancer, Metastatic", "PDAC - Pancreatic Ductal Adenocarcinoma" ], "interventions": [ { "name": "E-EDV-D682", "type": "DRUG" }, { "name": "EDV-GC", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab paclitaxel.", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Engeneic Pty Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 144, "start_date": "2026-01-12", "completion_date": "2028-09", "has_results": false, "last_update_posted_date": "2026-02-27", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 4, "location_summary": "El Segundo, California • Summit, New Jersey • New York, New York + 1 more", "locations": [ { "city": "El Segundo", "state": "California" }, { "city": "Summit", "state": "New Jersey" }, { "city": "New York", "state": "New York" }, { "city": "Maumee", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT07049055" }, { "nct_id": "NCT04602117", "title": "ISPY-P1.01:Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HER2-positive Breast Cancer", "HER2 Low", "SYD-985", "SYD985", "Vic-trastuzumab Duocarmazine", "Metastatic Cancer", "Metastatic Breast Cancer", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic", "HER2 Low Breast Cancer", "GastroEsophageal Cancer", "Gastroesophageal Adenocarcinoma", "Endometrium Tumor", "Ovarian Cancer", "Ovarian Carcinoma", "HER2-positive Gastric Cancer", "HER2-positive Metastatic Breast Cancer", "HER2 Mutation-Related Tumors", "HER-2 Protein Overexpression", "HER2 Low HR Positive", "HR Positive", "Hormone Receptor-positive Breast Cancer", "Estrogen Receptor Positive Tumor", "Progesterone Receptor-positive Breast Cancer", "Triple Negative Breast Cancer", "Hormone Receptor Negative Breast Carcinoma", "Bladder Cancer" ], "interventions": [ { "name": "Vic-trastuzumab duocarmazine (SYD985) + paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "QuantumLeap Healthcare Collaborative", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2021-07-28", "completion_date": "2021-11-17", "has_results": false, "last_update_posted_date": "2023-11-18", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 1, "location_summary": "Aurora, Colorado", "locations": [ { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT04602117" }, { "nct_id": "NCT01275677", "title": "Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HER2/Neu Positive", "Progesterone Receptor Positive", "Recurrent Breast Carcinoma", "Stage IA Breast Cancer AJCC v7", "Stage IB Breast Cancer AJCC v7", "Stage IIA Breast Cancer AJCC v6 and v7", "Stage IIB Breast Cancer AJCC v6 and v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIC Breast Cancer AJCC v7" ], "interventions": [ { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Docetaxel", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 3270, "start_date": "2011-02-08", "completion_date": "2025-06-02", "has_results": true, "last_update_posted_date": "2025-07-14", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 1259, "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 797 more", "locations": [ { "city": "Anniston", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT01275677" }, { "nct_id": "NCT00661193", "title": "S0709: Erlotinib With or Without Carboplatin and Paclitaxel in Stage IIIB or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 59, "start_date": "2008-12", "completion_date": "2016-12", "has_results": true, "last_update_posted_date": "2020-02-20", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 124, "location_summary": "Little Rock, Arkansas • Antioch, California • Berkeley, California + 90 more", "locations": [ { "city": "Little Rock", "state": "Arkansas" }, { "city": "Antioch", "state": "California" }, { "city": "Berkeley", "state": "California" }, { "city": "Burlingame", "state": "California" }, { "city": "Fremont", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00661193" }, { "nct_id": "NCT05117476", "title": "A Study of CLN-619 Alone and in Combination With Pembrolizumab in Advanced Solid Tumors", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumor", "NSCLC" ], "interventions": [ { "name": "CLN-619", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Carboplatin AUC 6", "type": "DRUG" }, { "name": "pemetrexed", "type": "DRUG" }, { "name": "Datopotamab deruxtecan-dlnk (Dato-DXd)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cullinan Therapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 440, "start_date": "2021-10-29", "completion_date": "2026-06", "has_results": false, "last_update_posted_date": "2025-11-24", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 12, "location_summary": "Birmingham, Alabama • Duarte, California • Irvine, California + 9 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT05117476" }, { "nct_id": "NCT04900623", "title": "Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HPV-Associated Oropharyngeal Squamous Cell Carcinoma", "HPV Positive Oropharyngeal Squamous Cell Carcinoma", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage", "HPV-Related Squamous Cell Carcinoma", "Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Clinical Stage", "HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Pathologic Stage" ], "interventions": [ { "name": "NavDx HPV ctDNA Testing", "type": "DEVICE" }, { "name": "Radiotherapy", "type": "RADIATION" }, { "name": "Chemotherapy drug", "type": "DRUG" } ], "intervention_types": [ "DEVICE", "RADIATION", "DRUG" ], "sponsor": "Jonathan Schoenfeld, MD, MPH", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 145, "start_date": "2021-07-02", "completion_date": "2032-06-01", "has_results": false, "last_update_posted_date": "2026-08-05", "last_synced_at": "2026-09-28T01:27:18.125Z", "location_count": 2, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04900623" } ] }